Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Clizia Zichi"'
Autor:
Letizia Procaccio, Valeria Merz, Morena Fasano, Vanja Vaccaro, Elisa Giommoni, Andrea Pretta, Silvia Noventa, Maria Antonietta Satolli, Guido Giordano, Clizia Zichi, Carmine Pinto, Camilla Zecchetto, Giulia Barsotti, Ferdinando De Vita, Michele Milella, Lorenzo Antonuzzo, Mario Scartozzi, Alberto Zaniboni, Rosella Spadi, Simona Casalino, Francesca Bergamo, Chiara De Toni, Davide Melisi, Sara Lonardi
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14337-14345 (2023)
Abstract Background The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) prog
Externí odkaz:
https://doaj.org/article/2ba909e629d843ce87c0d79ae0e1a3c6
Autor:
Giacomo Aimar, Chiara Paratore, Clizia Zichi, Donatella Marino, Elisa Sperti, Andrea Caglio, Teresa Gamba, Francesca De Vita, Massimo Di Maio
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 2, Iss 5, Pp 448-464 (2021)
Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identification of distinct molecular alterations with corres
Externí odkaz:
https://doaj.org/article/46affa1a81044e6ca6b2213bb2362c97
Publikováno v:
Drugs in Context, Vol 8, Pp 1-13 (2019)
For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have fai
Externí odkaz:
https://doaj.org/article/50a9e21c01b742a3b2c773216efa9347
Autor:
Clizia Zichi, Marco Tampellini, Marcello Tucci, Cristina Sonetto, Chiara Baratelli, Maria P. Brizzi, Giorgio V. Scagliotti
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-3 (2018)
Abstract Background Adenocarcinomas of the oral cavity are rare neoplasms, and only four cases of primary colonic adenocarcinoma of the tongue have ever been described in literature. Very few information about chemotherapy sensitiveness of this type
Externí odkaz:
https://doaj.org/article/1712670448f849b79eb7f01bf9b1a38e
Autor:
Giacomo Aimar, Donatella Marino, Clizia Zichi, Teresa Gamba, Andrea Caglio, Francesca De Vita, Elisa Sperti, Massimo Di Maio
Publikováno v:
Liver Cancer International. 3:90-98
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4518c3ee0bae3f157053d00ab47623b
https://doi.org/10.1002/lci2.50
https://doi.org/10.1002/lci2.50
Autor:
Giovanni Centonze, Marco Volante, Angelo Paolo Dei Tos, Alessandra Boccaccino, Giuseppe Aprile, Massimo Milione, Lorenzo Calvetti, Lorenza Rimassa, Giovanna De Maglio, Emanuela Dell'Aquila, Daniele Santini, Giulia Maddalena, Chiara Cremolini, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Massimo Di Maio, Paola Biason, Fotios Loupakis, Chiara Borga, Matteo Fassan, Valeria Smiroldo, Marta Schirripa, Federica Morano, Clizia Zichi, Nicoletta Pella, Roberta Salmaso, Filippo Pietrantonio, Elisa Sperti, F. Cortiula, Francesca Bergamo
Publikováno v:
European Journal of Cancer. 146:145-154
Background Neuroendocrine differentiation has been extensively associated with worse prognosis and to mechanisms of therapy resistance in several epithelial cancers. A high prevalence of neuroendocrine differentiation was recently described in V600EB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::281836252cf5fd3099ad131bc322ed0a
https://doi.org/10.1016/j.ejca.2021.01.016
https://doi.org/10.1016/j.ejca.2021.01.016
Autor:
Giulia Mentrasti, Luca Cantini, Clizia Zichi, Nicola D’Ostilio, Fabio Gelsomino, Erika Martinelli, Rita Chiari, Nicla La Verde, Renato Bisonni, Valeria Cognigni, Giada Pinterpe, Federica Pecci, Antonella Migliore, Giacomo Aimar, Francesca De Vita, Donatella Traisci, Andrea Spallanzani, Giulia Martini, Linda Nicolardi, Maria Silvia Cona, Maria Giuditta Baleani, Marco Luigi Bruno Rocchi, Rossana Berardi
Background Coronavirus disease 2019 (COVID-19) has triggered the disruption of health care on a global scale. With Italy tangled up in the pandemic response, oncology care has been largely diverted and cancer screenings suspended. Our multicenter Ita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1048d3553fef9cdd1876d1384d0ccd76
https://academic.oup.com/oncolo/article/27/9/e723/6639688?login=true
https://academic.oup.com/oncolo/article/27/9/e723/6639688?login=true
Autor:
Clizia Zichi, Nicoletta Pella, Fotios Loupakis, Vittorina Zagonel, Paola Biason, Chiara Cremolini, Giovanna De Maglio, Matteo Fassan, Claudia Mescoli, Massimo Di Maio, Valeria Smiroldo, Giada Munari, Alessandra Anna Prete, Sara Lonardi, Vincenzo Dadduzio, Emanuela Dell'Aquila, Marta Schirripa, Elisa Sperti, Giuseppe Aprile, Roberta Salmaso, Lorenzo Calvetti, Lorenza Rimassa, Lisa Salvatore, Daniele Santini, Carlotta Antoniotti, Vincenza Guzzardo, F. Cortiula, Rossana Intini, Federica Morano, Massimo Rugge, Filippo Pietrantonio, Francesca Bergamo
Publikováno v:
British Journal of Cancer
Background V600EBRAF mutated metastatic colorectal cancer (mCRC) is a subtype (10%) with overall poor prognosis, but the clinical experience suggests a great heterogeneity in survival. It is still unexplored the real distribution of traditional and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c363b90e0768855f77b46ae5bbfd8598
http://europepmc.org/articles/PMC6889398
http://europepmc.org/articles/PMC6889398
Publikováno v:
Drugs in Context, Vol 8, Pp 1-13 (2019)
Drugs in Context
Drugs in Context
For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have fai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a2255a3eff8143a341035c0df9248bc
https://doi.org/10.7573/dic.212577
https://doi.org/10.7573/dic.212577
Autor:
Orazio, Caffo, Viviana, Frantellizzi, Fabio, Monari, Luca, Galli, Renato Patrizio, Costa, Carmine, Pinto, Marcello, Tucci, Sergio, Baldari, Gaetano, Facchini, Roberto, Bortolus, Filippo, Alongi, Pierpaolo, Alongi, Davide, Donner, Stefano, Fanti, Andrea, Sbrana, Alessandra, Morabito, Cristina, Masini, Clizia, Zichi, Salvatore, Pignata, Eugenio, Borsatti, Matteo, Salgarello, Massimiliano, Spada, Ugo, De Giorgi, Giovanni, Lo Re, Enrico, Cortesi, Giuseppe, De Vincentis
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 36(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8c6d091e338a180aef9a968d4375bbe3
https://pubmed.ncbi.nlm.nih.gov/33769088
https://pubmed.ncbi.nlm.nih.gov/33769088